Evidence map›Paper›PMID 39196470›Full record

ArticleInternational journal of clinical oncology2024

Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON study.

Yoshiyuki Yamamoto, Hiroki Yukami, Tatsuro Yamaguchi, Hisatsugu Ohori, Sachiko Nagasu, Yoshinori Kagawa, Naotoshi Sugimoto, Hiromichi Sonoda, Kentaro Yamazaki, Atsuo Takashima and 16 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Yoshiyuki YamamotoDepartment of Gastroenterology, Clinical Medicine, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
Hiroki YukamiDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Tatsuro YamaguchiDepartment of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Japan.
Hisatsugu OhoriDepartment of Clinical Oncology, Ishinomaki Red Cross Hospital, Ishinomaki, Japan.
Sachiko NagasuDepartment of Surgery, Kurume University School of Medicine, Fukuoka, Japan.
Yoshinori KagawaDepartment of Surgery, Kansai Rosai Hospital, Amagasaki, Japan.
Naotoshi SugimotoDepartment of Clinical Oncology, Osaka International Cancer Institute, Osaka, Japan.
Hiromichi SonodaDivision of Gastrointestinal Surgery, Shiga University of Medical Science, Otsu, Japan.
Kentaro YamazakiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagaizumi, Japan.
Atsuo TakashimaGastrointestinal Medical Oncology Division, National Cancer Center Hospital, Chuo, Japan.
Hiroyuki OkuyamaDepartment of Clinical Oncology, Faculty of Medicine, Kagawa University, Takamatsu, Japan.
Hiroko HasegawaDepartment of Gastroenterology and Hepatology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Chihiro KondoDepartment of Medical Oncology, Toranomon Hospital, Minato, Japan.
Eishi BabaDepartment of Comprehensive Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Toshihiko MatsumotoDepartment of Medical Oncology, Himeji Red Cross Hospital, Himeji, Japan.
Yasuyuki KawamotoDivision of Cancer Center, Hokkaido University Hospital, Sapporo, Japan.
Masato KataokaDepartment of Surgery, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Yoshiaki ShindoGastroenterological Surgery, Nakadori General Hospital, Akita, Japan.
Toshiaki IshikawaDepartment of Medical Oncology, Juntendo University, Bunkyo, Japan.
Taito EsakiDepartment of Gastrointestinal and Medical Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan.
Yosuke KitoDepartment of Medical Oncology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
Takeo SatoDepartment of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
Taro FunakoshiDepartment of Therapeutic Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Toshifumi YamaguchiCancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Yasuhiro ShimadaDepartment of Clinical Oncology, Kochi Health Sciences Center, Kochi, Japan.
Toshikazu MoriwakiDepartment of Hepatology and Gastroenterology, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki City, Okayama, 710-0052, Japan. tmoriwak@gmail.com.ORCID http://orcid.org/0000-0001-7702-122X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFOLFOXIRI plus bevacizumab is a standard first-line chemotherapy for patients with metastatic colorectal cancer (mCRC). However, due to the severe toxicities, this regimen is not widely used. There is limited data on the real-world efficacy and safety.

methodsWe conducted a retrospective analysis of clinical data from mCRC patients who received FOLFOXIRI plus bevacizumab as first-line chemotherapy at 31 institutions. The initial dose was standardized according to the TRIBE regimen. Induction therapy was defined as a combination of oxaliplatin, irinotecan, and fluorouracil.

resultsOut of 104 patients who met the criteria, the median age was 58 years (range, 16-72). 81% of patients had an eastern cooperative oncology group performance status (PS) of 0. An initial dose reduction was observed in 63% of patients. The median number of preplanned induction therapy cycles was 12 (range, 4-12). The completion of scheduled induction therapy cycles was observed in 45% of patients, with treatment-related toxicities being the main reason for discontinuation (63%). The median progression-free survival and overall survival were 12.8 months (95% CI, 10.6-15.0) and 27.9 months (95% CI 21.6-34.2), respectively. The objective response rate and disease control rate were 63.7% and 98.9%, respectively. The R0 resection rate was 21.2%. The main grade 3 or higher toxicities were neutropenia (51%), febrile neutropenia (10%), and nausea/vomiting (5%). No treatment-related deaths were observed.

conclusionIn a real-world clinical setting, FOLFOXIRI plus bevacizumab demonstrated efficacy and safety comparable to previous clinical trials.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBevacizumabCamptothecinColorectal NeoplasmsFluorouracilLeucovorinOrganoplatinum CompoundsAdolescentAdultAgedFemaleHumansIrinotecanMaleMiddle AgedNeoplasm MetastasisBevacizumabCamptothecinFluorouracilIrinotecanLeucovorinOrganoplatinum CompoundsBevacizumabColorectal cancerFOLFOXIRIReal-world outcomeTriplet

Identifiers

PMID39196470

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.